BioLargo Posts $15.2M Net Loss, Revenue Halves in 2025 Amid Operational Challenges
Summary
BioLargo reported a significant $15.2 million net loss for 2025 on $7.8 million in revenue, with year-end cash at $3.9 million. This confirms a substantial decline from 2024 revenue of $17.8 million, representing a 56% drop. This news follows yesterday's report indicating a "significant deterioration" in 2025 results and a 56% revenue plummet, now quantified with specific figures from the company's 2025 Annual Report and an 8-K filing. The $15.2 million net loss is highly material relative to the company's market capitalization, indicating severe operational challenges and significant cash burn. Investors will be closely watching for strategies to improve profitability and revenue growth, as well as potential financing needs given the current financial performance.
At the time of this announcement, BLGO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $53.2M. The 52-week trading range was $0.14 to $0.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.